These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2476606)

  • 21. Effects of pimobendan (UD-CG 115 BS) on left ventricular inotropic state in conscious dogs and in patients with heart failure.
    Pouleur H; Hanet C; Schröder E; Col J; Van Mechelen H; Etienne J; Rousseau MF
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S18-22. PubMed ID: 2478787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemodynamic performance during exercise in patients with severe chronic congestive heart failure before and after a single dose of pimobendan.
    Hagemeijer F
    J Cardiovasc Pharmacol; 1994 May; 23(5):741-6. PubMed ID: 7521456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemodynamic profile of the cardiotonic agent pimobendan.
    van Meel JC; Diederen W
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S1-6. PubMed ID: 2478784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Reduction in left ventricular volume and improvement in hemodynamics following intravenous administration of pimobendan (UDGG 115 BS) in dilated cardiomyopathy].
    Permanetter B; Sebening H; Busch U; Lutilsky L
    Z Kardiol; 1990 Aug; 79(8):565-72. PubMed ID: 2220013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute hemodynamics of pimobendan in chronic heart failure. A comparative crossover study of captopril and pimobendan.
    Tsuda T; Izumi T; Kodama M; Hanawa H; Takahashi M; Suzuki M; Aizaki T; Uchiyama H; Kuwano H; Shibata A
    Jpn Heart J; 1992 Mar; 33(2):193-203. PubMed ID: 1593749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.
    Fitton A; Brogden RN
    Drugs Aging; 1994 May; 4(5):417-41. PubMed ID: 8043944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular effects of the positive inotropic agents pimobendan and sulmazole in vivo.
    von Meel JC
    Arzneimittelforschung; 1985; 35(1A):284-8. PubMed ID: 4039168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study).
    Effects of Pimobendan on Chronic Heart Failure Study (EPOCH Study)
    Circ J; 2002 Feb; 66(2):149-57. PubMed ID: 11999639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group.
    Kubo SH; Gollub S; Bourge R; Rahko P; Cobb F; Jessup M; Brozena S; Brodsky M; Kirlin P; Shanes J
    Circulation; 1992 Mar; 85(3):942-9. PubMed ID: 1537130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemodynamic effects of intravenous pimobendan in patients with left ventricular dysfunction.
    Remme WJ; Wiesfeld AC; Look MP; Kruyssen HA
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S41-4. PubMed ID: 2478791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute effects of a single low oral dose of pimobendan on left ventricular systolic and diastolic function in patients with congestive heart failure.
    Ishiki R; Ishihara T; Izawa H; Nagata K; Hirai M; Yokota M
    J Cardiovasc Pharmacol; 2000 Jun; 35(6):897-905. PubMed ID: 10836724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of pimobendan in 170 cats (2006-2010).
    Macgregor JM; Rush JE; Laste NJ; Malakoff RL; Cunningham SM; Aronow N; Hall DJ; Williams J; Price LL
    J Vet Cardiol; 2011 Dec; 13(4):251-60. PubMed ID: 22030289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group.
    Remme WJ; Krayenbühl HP; Baumann G; Frick MH; Haehl M; Nehmiz G; Baiker W
    Eur Heart J; 1994 Jul; 15(7):947-56. PubMed ID: 7925517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of pimobendan in the treatment of heart failure.
    Duncker DJ; van Dalen FJ; Hartog JM; Lamers JM; Rensen RJ; Saxena PR; Verdouw PD
    Arzneimittelforschung; 1986 Dec; 36(12):1740-4. PubMed ID: 3032212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Acute and chronic effects of UDCG 115 BS (pimobendan) in patients with advanced myocardial failure].
    Permanetter B; Baumann G; Wirtzfeld A; Günes S; Stinshoff M; Klein G
    Z Kardiol; 1989 May; 78(5):335-42. PubMed ID: 2660451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemodynamic effects of a new type III phosphodiesterase inhibitor (CI-914) for congestive heart failure.
    Jafri SM; Burlew BS; Goldberg AD; Rogers A; Goldstein S
    Am J Cardiol; 1986 Feb; 57(4):254-9. PubMed ID: 3511661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of pimobendan and its active metabolite, UD-CG 212 Cl, on Ca2+-activated K+ channels in vascular smooth-muscle cells.
    Chen CH; Nakaya Y; Minami K; Kubo M
    J Cardiovasc Pharmacol; 1997 Dec; 30(6):739-43. PubMed ID: 9436812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute hemodynamic effect of oral MDL 17,043 in severe congestive heart failure.
    Uretsky BF; Generalovich T; Reddy PS; Salerni R; Valdes AM; Spangenberg RB; Lang JF; Okerholm RA
    Am J Cardiol; 1984 Aug; 54(3):357-62. PubMed ID: 6235735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma concentration profile of orally administered pimobendan and plasma brain natriuretic peptide level in patients with severe heart failure.
    Wakaumi M; Shiga T; Naganuma M; Matsuda N; Tatami S; Kasanuki H
    Cardiovasc Drugs Ther; 2003 May; 17(3):291-3. PubMed ID: 14669747
    [No Abstract]   [Full Text] [Related]  

  • 40. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
    J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.